

Attachment of Small Molecule with DNA and RNA

Dr.Subhasis Basu, IIP-Post Doctoral Fellow,
Eudoxia Research Center India,
Eudoxia Research University, New Castle USA.
Email: subhaasis1@gmail.com

A. Abstract:

The four natural DNA bases A-Adenosine, T-Thymine, G-Guanine, C-Cytosine are associated in base pairs as (A=T and G≡C), allowing the attached DNA strands to assemble into the canonical double helix of DNA which is duplex of DNA, also known as *B*-DNA. The intrinsic supramolecular properties of nucleobases make other associations possible such as base triplets or quartets, which thus translates into a diversity of DNA structures is ripe with approximately 20 letters, (from A- to Z-DNA); however, only a few of them are being considered as key players in cell biology and by extension, valuable targets for chemical biology invention. In the present review, we summarise (1) what is known about alternative DNA structures (2) what are they? (3) When, where and how they fold?

These are all proceeded to discuss further and those considered nowadays as valuable therapeutic targets. We discuss in more detail the molecular tools (ligands) that have been recently developed to target these structures. In order to intervene in the biological processes, particularly three and four ways of DNA junctions are involved there. This new and simulating chemical biology playground allows for devising innovative strategies to fight against genetic diseases.

Key words:

DNA- structure, A to Z- DNA, folding, ligands and target structures, genetic drug design. RNA- structure, A to Z- RNA, folding, ligands and target structures, genetic drug design.

B.INTRODUCTION:“Attachment of small molecule with DNA and RNA.”

The primary function of RNA is to create proteins via translation. RNA carries genetic information that is translated by ribosome into various proteins necessary for cellular processes. mRNA, rRNA, and tRNA are the three main types of RNA involved in protein synthesis mRNA (messenger RNA): it provides the template for protein synthesis during translation. tRNA (transfer RNA): it brings amino acids and reads the genetic code during translation. rRNA (ribosomal RNA): it plays a structural and catalytic role during translation.

The four natural RNA bases A-Adenosine, U-Uracil, G-Guanine, C-Cytosine are associated in base pairs as (A=U and G≡C), allowing the attached DNA strands to assemble into the canonical double helix of RNA which is duplex of RNA, also known as *B*-RNA. The intrinsic supramolecular properties of nucleobases make other associations possible such as base triplets or quartets, which thus translates into a diversity of RNA structures is ripe with approximately 20 letters, (from A- to Z-RNA); however, only a few of them are being considered as key players in cell biology and by extension, valuable targets for chemical biology invention. Uracil is replaced by Thymine in case of DNA. In the present review, we summarise (1) what is known about alternative RNA structures (2) what are they? (3) When, where and how they fold?

These are all proceeded to discuss further and those considered nowadays as valuable therapeutic targets. We discuss in more detail the molecular tools (ligands) that have been recently developed to target these structures. In order to intervene in the biological processes, particularly three and four ways of RNA junctions are involved there. This new and simulating chemical biology playground allows for devising innovative strategies to fight against genetic diseases.

RNA is crucial for gene expression and regulation. Recent advances in understanding of RNA biochemistry, structure and molecular biology have revealed the importance of RNA structure in cellular processes and diseases. Various approaches to discovering drug-like small molecules that target RNA structure have been developed. This review provides a brief introduction to RNA structural biology and how RNA structures function as disease regulators. We summarize approaches to targeting RNA with small molecules and highlight their advantages, shortcomings and therapeutic potential. RNA importance is increasingly appreciated as regulators of human diseases and consequently as potential drug targets. Novel methods to target RNA structure with small molecules rather than RNA sequence have been developed. Knowledge and principles of RNA structure are highly desired to develop more effective RNA structure-targeting drugs.

The four natural DNA bases A-Adenosine, T-Thymine, G-Guanine, C-Cytosine are associated in base pairs as ($A=T$ and $G=C$), allowing the attached DNA strands to assemble into the canonical double helix of DNA which is duplex of DNA, also known as *B*-DNA. The intrinsic supramolecular properties of nucleobases make other associations possible such as base triplets or quartets, which thus translates into a diversity of DNA structures is ripe with approximately 20 letters, (from A- to Z-DNA); however, only a few of them are being considered as key players in cell biology and by extension, valuable targets for chemical biology invention. In the present review, we summarise (1) what is known about alternative DNA structures (2) what are they? (3) When, where and how they fold?

These are all proceeded to discuss further and those considered nowadays as valuable therapeutic targets. We discuss in more detail the molecular tools (ligands) that have been recently developed to target these structures. In order to intervene in the biological processes, particularly three and four ways of DNA junctions are involved there. This new and simulating chemical biology playground allows for devising innovative strategies to fight against genetic diseases.

The DNA alphabet is naturally restricted to four letters, i.e. A for adenine, C for cytosine, G for guanine and T for thymine (1,2) (although some creative scientists have achieved the juggling act to expand it to 6 in living semi synthetic organisms (3,4), and then 8 (5), mimicking what was discovered in bacteriophages >4 decades ago) (6–9). In contrast, the

DNA structure alphabet is far richer, with >20 letters used to date as descriptors of secondary structures). The canonical, so called Watson–Crick, structure is referred to as B-DNA (as the X-ray crystallographic structure was obtained by Rosalind Franklin after hydration of a first sample ('A') of high-quality DNA provided by Rudolf categorized as a non-B-DNA structure, spanning from A-DNA (thus, dehydrated duplex) (11) to Z-DNA (duplex of inverted helicity, Z for zigzag) (10,15).

The central dogma of biology, heralded by Francis Crick in 1957 (16,17), has placed the B-DNA at the very centre of all molecular biology efforts invested, and discoveries made, after the elucidation of its double helix structure (2,13,18). This has kept the limelight away from reports published in succeeding years on the ability of DNA to fold into a variety of non-B-DNA structures (Figure 1), including: the triple helix (or triplex (19), termed H-DNA given its homopurine (hPu)/homopyrimidine (hPy) nature, also referring to hinged DNA) (20), first identified in RNA in 1957(21) before being characterized in DNA in 1979; (22) the G-quartet in 1962 (23), the constitutive unit of the quadruple helix G-quadruplex (G4-DNA, or G-DNA) whose formation was demonstrated in 1988; (24) the tetra-stranded four-way DNA

junction proposed as a model to explain gene conversion in 1964 by Robin Holliday (consequently called the Holliday junction) (25), predicted in 1966 (26) and demonstrated in vitro (and termed cruciform DNA, C- DNA) in the early 80s; (27,28) the Z-DNA first detected in 1967 (as a B-DNA of inverted, left-handed helicity) (29) before being firmly confirmed in 1979 (30), etc.

C. Literature Review:

C.1. Methodology in terms of Systematic Review and Literature Review in broad aspect:

As per the above available primary data of the research I have searched DNA/RNA Structure in the Mendeley search Engine, here I have found more than 99000 papers. To minimize and to get best result I have changed the searched words into various option, where only journal papers and Thesis from year 2020 to 2024 , which give me best results and was shorten the work into nearly 29032 papers in that searching date 25/11/2023. Out of this finding the attachments of small molecules shorten to nearly 7292 open access journal papers which shorten to m I have made a link of nearly 200 papers in the Mendely Reference Management Software where a prior registration with my email account was done. After that I have made an Excel Sheet where searching tools, paper name, Authors, Abstracts, volume, issue date, Key words, URL, Conclusion etc. data were tabulated. Apart from that Departmental library/central Library books also help me in this review work. But systematic review is done with the help of the mentioned software. It is true the available data are different in different date and time. To get best result it should be carried out in the same date with searching tools and words etc. Some basic steps has been followed to carry out this systematic review of this available primary data on the taken topic and basic ideas.

First in this systematic review process I have searched on the topic of (a) coral reef zone in India. (b) The cause of bleaching process there. With the help of various searching engine I have found the best available papers or book on it. Here the following process has been described in the term of systematic Review. Total no of shorted papers in the excel sheet is 200.

Different Searching results: (14)

(1) **Screening:** From Scopus-Elesveiser searching using key words as “DNA/RNA structure, searching date 25/11/2022, total findings was 29038 for at any time, since 2020 total findings minimizes as 7292, where only open access journals.

- (2) **Screening:** small molecules attachments Elsevier.com results nearly 200, changing key words “attachments with small molecules with DNA/RNA” results only 350 available for open access papers.
- (3) **3rd Screening:** Changing date 23/12/2023 time 11.35A.M using key words” coral bleaching and India” from Elsevier, all results as 200 where Web page: 73, Books: 45, Journals: 102, thesis: remaining
- (4). **4th Screening:** Changing key words as in the same Elsevier in the same date “cloning of DNA, results nearly same
- (5). **5th Screening:** Changing key words as in the published journal: 200,
- (6). **Screening:** Changing the key words DNA replication also going through abstract suggested papers result same.

Systematic Review is done in the Excel Sheet, where the 56 papers data are inputted in tabular form. Some of papers which has been carried out there are representing in tabular form in word format in below. The data in tabular form helps us to get best results on research work progress on the above topic. Various graphical representation or charts could be drawn. And from Results conclusion could be drawn.

In the Excel sheet we input the following data in table-1

Item Type-SL. No	
Publication Year	
Search Engine	
Journal or Book name.	
Search Strings	
Author Name	
Title	
Publication Title	
Issue	
Volume	
Abstract	
Key Words	
Methodology	
Sample Size	
STUDY Area	

Result	
Conclusion	
Paper Publication	
Citation	


For example referred from Appendix the carried out systematic review in the form of Excel sheet, comes in the following word form in Table-2:

Item Type-1	Journal Articles
Publication Year	2022
Search Engine	Mendeley.
Journal or Book name.	Scopus, Science Direct, Pubmade etc
Search Strings	DNA/RNA structure.
Author Name	Goronzy, Isabel N., Quinodoz, Sofia A., Jachowicz, Joanna W., Ollikainen, Noah, Bhat, Prashant, Guttman, Mitchell
Title	Simultaneous mapping of 3D structure and nascent RNAs argues against nuclear compartments that preclude transcription
Publication Title	Simultaneous mapping of 3D structure and nascent RNAs argues against nuclear compartments that preclude transcription
Issue	9
Volume	41
Abstract	Mammalian genomes are organized into three-dimensional DNA structures called A/B compartments that are associated with transcriptional activity/inactivity. However, whether these structures are simply correlated with gene expression or are permissive/impermissible to transcription has remained largely unknown because we lack methods to measure DNA organization and transcription simultaneously. Recently, we developed RNA & DNA (RD)-SPRITE, which enables genome-wide measurements of the spatial organization of RNA and DNA. Here we show that RD-SPRITE measures genomic structure surrounding nascent pre-mRNAs and maps their spatial contacts. We find that

	transcription occurs within B compartments—with multiple active genes simultaneously co localizing within the same B compartment—and at genes proximal to nucleoli. These results suggest that localization near or within nuclear structures thought to be inactive do not preclude transcription and that active transcription can occur throughout the nucleus. In general, we anticipate RD-SPRITE will be a powerful tool for exploring relationships between genome structure and transcription.
Key Words	DNA Structure, A/B Compartment, genes. RD-SPRITE.
Methodology	3D structure
Sample Size	Large
STUDY Area	Indian Coral reef bleaching area.
Result	This work attempts to Study the link between sustainability, SDG goals of 2030 given by United Nations and coral bleaching.
Conclusion	This work attempts to Study the link between sustainability, SDG goals of 2030 given by United Nations and coral bleaching. In this work study period is focused from 1985 to 2021 in the Indian coral reef bleaching areas.
Paper Publication	Yes, International
Citation	https://doi.org/10.1016/j.celrep.2022.111730

C.2. Result Discussion

Flowchart of the screened articles in chart in Figure-1:





Systematic review work for bibliography/ references has done as per training and exposures gained from International exposures from IIP- International work shops and seminar, arranged by Eudoxia research centre India, and Eudoxia Research University, USA

C.3. Result Discussion

From Excel sheet of systematic Review, applying filters give this following table-3

Year	No Of Publication
2024	2
2023	931
2021	1299
2020	1341

Putting into Bar diagram results shows as follows in graph-1,2 Figure-2,3:



Literature review shows the work of attachments of small molecules with DNA/RNA could be a great work in terms of paper publication and other Noble works in this Analytica Chemistry area in this incoming years with huge job prospects in India and USA .

D. Research Methodology:

D.1.Replication (A Theoretical Methodology Discussion):

is the process by which a double-stranded DNA molecule is copied to produce two identical DNA molecules. DNA replication is one of the most basic processes that occur within a cell.

What are the 4 steps of replication?(Figure-5)



- Step 1: Replication Fork Formation. Before DNA can be replicated, the double stranded molecule must be “unzipped” into two single strands. ...
- Step 2: Primer Binding. The leading strand is the simplest to replicate. ...
- Step 3: Elongation. ...
- Step 4: Termination




Figure-6,DNA REPLICATION PROCESS







Figure-7,8;DNA Replication



D.2.The complete process of DNA Replication involves the following steps:

- Recognition of initiation point. Endonuclease enzyme.
- Unwinding of DNA.
- Template DNA.
- RNA Primer.
- Chain Elongation.

- Replication forks. Okazaki fragments continuous strand. discontinuous strand. ...
- Proof reading.
- Removal of RNA primer and completion of DNA strand.(figure-9,10 replication steps)



The four main enzymes involved in DNA replication are DNA helicase, RNA primase, DNA polymerase, and DNA ligase. These enzymes work together to open up the DNA strand in replication bubbles and copy the DNA strands semi-conservatively

What are the 5 types of DNA replication?


D.3. The three models for DNA replication

- Conservative. Replication produces one helix made entirely of old DNA and one helix made entirely of new DNA.
- Semi-conservative. Replication produces two helices that contain one old and one new DNA strand.
- Dispersive.
- What is an example of DNA replication?

Replication

is the process by which a cell copies its DNA prior to division. In humans, for example, each parent cell must copy its entire six billion base pairs of DNA before undergoing mitosis.

D.4. DNA CLONING (Figure-11)



D.5. What are the 4 steps in cloning?(A Theoretical Methodology Discussion):

In the classical restriction enzyme digestion and ligation cloning protocols, cloning of any DNA fragment essentially involves four steps:

- isolation of the DNA of interest (or target DNA),
- ligation,
- transfection (or transformation), and.
- a screening/selection procedure
- What is cloning method?

- Cloning is a technique scientists use to make exact genetic copies of living things. Genes, cells, tissues, and even whole animals can all be cloned. Some clones already exist in nature.

D.6. Uses of DNA Clone

In basic research labs, biologists often use DNA cloning to build artificial, recombinant versions of genes that help them understand how normal genes in an organism function.


Why use PCR for cloning?

PCR cloning is a rapid method for cloning genes, and is often used for projects that require higher throughput than traditional cloning methods can accommodate. It allows for the cloning of DNA fragments that are not available in large amounts.

E.1. Result And Discussion

The topological diversity of DNA stems from supramolecular chemistry considerations: nucleobases (A, C, G, T) associate through the formation of hydrogen bonds (H-bonds), two in the A⁼T base pair, three in the G-C base pair, allowing for a dynamic assembly/disassembly without substantial energy penalty. However, nucleobases are not exclusive in their H-bond-mediated association, and >20 different pairing modes are possible involving two of the four letters (31), offering

Figure-12(H Bonding in DNA)



The canonical, so called Watson–Crick, structure is referred to as B-DNA (as the X-ray crystallographic structure was obtained by Rosalind Franklin after hydration of a first sample (‘A’) of high-quality DNA provided by Rudolf categorized as a non-B-DNA structure, spanning from A-DNA (thus, dehydrated duplex) (11) to Z-DNA (duplex of inverted helicity, Z for zigzag) (10,15).

The central dogma of biology, heralded by Francis Crick in 1957 (16,17), has placed the B-DNA at the very Centre of all molecular biology efforts invested, and discoveries made, after the elucidation of its double helix structure (2,13,18). This has kept the limelight away from reports published in succeeding years on the ability of DNA to fold into a variety of non-B-DNA structures (Figure 1), including: the triple helix (or triplex (19), termed H-DNA given its homopurine (hPu)/homopyrimidine (hPy) nature, also referring to hinged DNA) (20), first identified in RNA in 1957

(21) before being characterized in DNA in 1979; (22) the G-quartet in 1962 (23), the constitutive unit of the quadruple helix G-quadruple (G4-DNA, or G-DNA) whose formation was demonstrated in 1988; (24) the tetra-stranded four-way DNA junction proposed as a model to explain gene conversion in 1964 by Robin Holliday (consequently called the Holliday junction) (25), predicted in 1966 (26) and demonstrated in vitro (and termed cruciform DNA, C- DNA) in the early 80s; (27,28) the Z-DNA first detected in 1967 (as a B-DNA of inverted, left-handed helicity) (29) before being firmly confirmed in 1979 (30), etc.

The topological diversity of DNA stems from supramolecular chemistry considerations: nucleobases (A, C, G, T) associate through the formation of hydrogen bonds (H-bonds), two in the A T base pair, three in the G C base pair, allowing for a dynamic assembly/disassembly without substantial energy penalty. However, nucleobases are not exclusive in their H-bond-mediated association, and >20 different pairing modes are possible involving two of the four letters (31), offering a first degree of topological diversity (base pairing). Also, nucleobases can donate/accept H-bonds through both their Watson–Crick (2) and Hoogsteen (32,33) faces, which are not mutually exclusive and thus permit the formation of base triplets (34) and quartets (23), offering a second degree of topological diversity (strandness). On the basis of the above, the structural pluralism of nucleic acids is anything but surprising.

The reason why these alternative structures have been overlooked for years is that their existence in a cellular context is challenged by the chromatin environment, in which the dense DNA packaging massively favors B-DNA. This has made the demonstration of their existence in vivo-like conditions daunting, and the chemical biology tools required to do so have reached the necessary degree of maturity only recently (e.g. the visualization of G4s in fixed cells by the antibody BG4 in 2013 (35), in live cells by the small molecule SiR-PyPDS in 2020) (36). Also, the rules that dictate their formation in the genome

are poorly understood even if the sequences these structures fold from (i.e. repeated sequences) are known to be both abundant and widespread in the human genome (repetitive DNA elements cover roughly half of our genome) (37,38). Non-B-DNA-prone sequences can be inverted repeats (IR, involved in the formation of four-way DNA junction (FWJ), or cruciform DNA, Figures 1 and 2A), direct repeats (DR, involved in the formation of three-way DNA junction (TWJ), also termed slipped-strand DNA, slipped DNA or S-DNA (39), Figures 1 and 2B), mirror repeats (MR, involved in the formation of H-DNA) (38,40,41), or short tandem repeats (STR, involved in the formation of hairpin DNA, G4-DNA and i-motif (iM or I-DNA, Figure 1) depending of the repeated motif) (42). Thanks to recent computational analyses of an entirely sequenced human genome, the abundance of the non-B-DNA-prone sequences can be calculated: it is established that the least abundant motif is MR, with ca. 70 000 occurrences (ca. 2/100 kb), while the most abundant motif, IR, has >6000000 occurrences (ca. 206/100 kb) (41). However, despite the abundance of sequences that could give rise to non-B-DNA structures, the timing and kinetics of their folding are still poorly understood. Also, this folding requires the involved sequences to be freed from the duplex


Constraint (i.e. open chromatin, damaged DNA), their formation is thus transient only and subjected to a permanent and careful surveillance by ad hoc enzymes (e.g. helicases) (43), which make their formation even less likely. This thus explains why non-B-DNA structures have not been considered as reliable genetic elements (and targets) for years. Despite all these constraints, some of these structures (G4s, iMs) have been isolated and identified by sequencing methods. Efforts invested in vitro (that is, with purified DNA fragments) confirmed their widespread formation in the human genome (with >500 000 G4- (44) and iM-forming (45)

Sequences), but not only (46) (e.g. >25 000 G4- (47) and iM-forming (48) sequences in plants) (49). Investigations performed in vivo distinctly highlighted the suppressive role of chromatin for non-B-DNA structure formation as only ca. 1% of the G4s detected in vitro (G4-seq) (44) were detected in vivo (G4 ChIP-seq) (50). More globally, a combination of footprinting experiments (KMnO₄/S1 nuclease) and genome-wide sequencing (ssDNA-seq) allowed to link DNA regions in mammalian cells with non-B-DNA structures (C-, G-, H- and Z-DNA, ca. 20 000 motifs each) and then, these structures with regions involved in gene expression regulation (51). Further combining nuclease cleavage (S1 and P1) and sequencing (S1-END-seq and P1-END-seq, respectively) revealed that C- and H-DNA formation (at dinucleotide (TA)_n repeats and hPu/hPy repeats (e.g. (GAA)_n), respectively) is both widespread in human cells but also strongly dependent on the cell status (cancerous versus non-cancerous cells) (52,53). These results, beyond confirming the existence of non-B-DNA structures in vivo, provide also a strong correlation between structure-prone sequences and both mutability and genetic instability (52) (often

referred to as to RIM, for repeat-induced mutagenesis) (54,55). Indeed, their widespread and no uniform distribution across our genome is significantly enriched in regulatory regions, and the distribution quite often overlaps with that of reported hotspots, i.e. regions prone to undergo breakage, deletions and translocations (38,41,55,56). This explains why repeated sequences are carefully patrolled and tightly controlled by genome surveillance systems, notably the DNA damage response (DDR) machinery (57–59). As indicated above, to adopt higher-order structures, these sequences must be relieved from their duplex constraint and reannealed with misalignment or slippage. Their folding is thus dependent on, and coupled with, DNA trans- actions (transcription, replication) and repair. This makes them interesting targets for therapeutic approaches aimed at inflicting damage to highly active, that is, rapidly dividing cells. Indeed, once folded, these thermodynamically stable structures might act as roadblocks to polymerases, pausing and/or stalling their processivity, which is recognized as a situation of crisis (DNA damage) (60–63). It is therefore unsurprising that chemical biologists soon envisioned an original strategy in which the transient stabilization of non- B-DNA structures by small molecules (so called ligands) could be exploited to foster this situation of crisis notably in rapidly dividing, that is, cancer cells (62,64). The relevance of this approach is further substantiated by the fact that cancer cells are generally DDR-impaired (57), which makes them more sensitive to DNA damage-inducing agents than healthy cells. This explains why many of the therapeutics currently used in the clinic damage DNA, although through different modalities (65). However, these therapeutics target B-DNA (or their associated proteins such as topoisomerases) but none of them target non-B-DNA structures. This is clearly the major caveat of this field, which deserves to be addressed soon in order to lend credence to its strategic relevance. The most advanced molecule, the G4-stabilizer CX-5461 is currently in phase I (clinicaltrials.gov NCT02719977) (66) against advanced solid tumors (its parent molecule CX-3543, also known as Quarfloxin, was stopped after phase I). Without a successful example of non-B-DNA targeting agent in the clinic, this field will keep on suffering from a lack of legitimacy. Yet, in contrary to B-DNA, which offers poorly defined binding sites only (i.e. minor and major grooves, intercalation in between 2 bp), non-B-DNA structures offer a broad variety of structurally well-defined ligand binding sites, which makes highly selective targeting with small molecules possible. Chief among them are the G4-DNA (67–69), which display two G-quartets surrounded by flexible loops, and DNA junctions (70–72), in which the junction point between the duplex arms (3 duplex arms for TWJ; four arms for FWJ) creates a cavity prone to welcome small molecules (vide infra). The recent developments described in this review will be focused on the targeting of DNA junctions, as that of G4-DNA is regularly covered by authoritative reviews (68,69,73–77) to which interested readers are invited to refer. These developments offer this field a shining message of hope, as these new ligands allow for a specific targeting of DNA junctions (78), yet in in vitro and cell-

based assays only to date, which bears significant potential for delivering soon a new generation non-B-DNA targeting therapeutics for which the demonstration of clinical efficacy is greatly expected.

(FIGURE-13,FWJ,TWJ)



The canonical, so called Watson–Crick, structure is referred to as B-DNA (as the X-ray crystallographic structure was obtained by Rosalind Franklin after hydration of a first sample (‘A’) of high-quality DNA provided by Rudolf categorized as a non-B-DNA structure, spanning from A-DNA (thus, dehydrated duplex) (11) to Z-DNA (duplex of inverted helicity, Z for zigzag) (10,15).

The central dogma of biology, heralded by Francis Crick in 1957 (16,17), has placed the B-DNA at the very Centre of all molecular biology efforts invested, and discoveries made, after the elucidation of its double helix structure (2,13,18). This has kept the limelight away from reports published in succeeding years on the ability of DNA to fold into a variety of non-B-DNA structures (Figure 1), including: the triple helix (or triplex (19), termed H-DNA given its homopurine (hPu)/homopyrimidine (hPy) nature, also referring to hinged DNA) (20), first identified in RNA in 1957

(21) before being characterized in DNA in 1979; (22) the G-quartet in 1962 (23), the constitutive unit of the quadruple- helix G-quadruple (G4-DNA, or G-DNA) whose formation was demonstrated in 1988; (24) the tetra-stranded four-way DNA junction proposed as a model to explain gene conversion in 1964 by Robin Holliday (consequently called the Holliday junction) (25), predicted in 1966 (26) and demonstrated in vitro (and termed cruciform DNA, C- DNA) in the early 80s; (27,28) the Z-DNA first detected in 1967 (as a B-DNA of inverted, left-handed helicity) (29) before being firmly confirmed in 1979 (30), etc.


The topological diversity of DNA stems from supramolecular chemistry considerations: nucleobases (A, C, G, T) associate through the formation of hydrogen bonds (H-bonds), two in the A T base pair, three in the G C base pair, allowing for a dynamic assembly/disassembly without substantial energy penalty. However, nucleobases are not exclusive in their H-bond-mediated association, and >20 different pairing modes are possible involving two of the four letters (31), offering a STRUCTURE, FUNCTIONS AND TARGETING OF DNA JUNCTIONS.

The field of non-B-DNA structures and related ligands was undoubtedly pioneered by Neville Kallenbach (72,79). In a series of articles published in the mid 80's-mid 90's, he provided both biophysical characterizations (e.g. by calorimetry (80), gel electrophoresis (81), chemical footprinting(82,83), etc.) of DNA junctions (but also of G4-DNA) (84,85) and the first insights into how small molecules (Figure 3A), mostly fluorescent dyes, i.e. the DNA labelling agent propidium iodide (86), the cyanine stains-all (87), the porphyrin TMPyP4 (88), but also cleaving agents such as methidium-propyl-EDTA-Fe(II) (MPE-Fe) (89), interact with them (and with G4s) (90). Of course, these studies were limited to in vitro investigations and the selectivity for DNA junctions over B-DNA, of utmost importance for chemical biology and medicinal chemistry, was not investigated. Anyway, these studies were instrumental in that they spurred on research aiming at ultimately investigating the cellular effects on these new genetic targets and molecular tools (further discussed below).


E.2. Targeting four-way DNA junctions(FWJ)

As indicated above, the existence of a four-stranded DNA structure was postulated by Robin Holliday in 1964 as an intermediate in homologous recombination (HR) (25,91). The possible formation of a central four-way junction intermediate (a 'chiasma') had already been discussed by Joseph G. Gall in 1954 (92), as a basis for the crossing-over mechanism, i.e. the reciprocal exchange of segments along pairs of homologous chromosomes. However, heroic efforts were needed to obtain a structural confirmation of the FWJ organization of this intermediate: various biochemical and physicochemical methods were implemented, including gel electrophoresis (93–95), fluorescence energy transfer (FET (96,97), then reported as FRET (98,99), for fluorescence resonance energy transfer), birefringence decay (100), and nuclear magnetic resonance (NMR) (101,102), along with some imaging techniques such as scanning electron microscopy (SEM) (103) and atomic force measurements (AFM) (104). Among these techniques, X-ray crystallography played a central role: (105) solid state analyses were indeed instrumental to solve the structure of FWJ, alone (106,107) or in interaction with enzymes in charge of the recombination (the resolvase RuvA (108,109) or the recombinase Cre (110), vide infra) (111) and then, small molecules (vide infra). All these techniques concurred in demonstrating the organisation of the FWJ, with its four arms

that either extend from opposite sides of the central cavity, which is therefore wide open (the so-called open planar X-structure), or stack on each other two by two (the so-called stacked X-structure), which consequently closes the central cavity (Figure 4A) (70). The initial junction structure was obtained while studying DNA mismatches, and a later study revealed that, in the crystal structure, junction formation is sequence dependent (112). These authors carried out a systematic study of the decamer sequences CCn1n2n3N1N2N3GG, where N can be any of the four common nucleotides, and n are specified accordingly to maintain the IR motif and thus self-complementarity of the sequences. From the 64 possible combinations, they concluded that the d(CCGGTACCGG) sequence gave the junction form under all conditions tested, whereas other sequences could be in equilibrium with A- or B-DNA forms. A way to control the conformation is the covalent binding of psoralen: (113) the closely related sequence d(CCGCTAGCGG) was found to crystallise as a B-form duplex, but the binding of psoralen after laser irradiation at the TA/TA step led to the stabilisation of the junction (Figure 14). More generally, the X-ray structures obtained in presence of enzymes and ligands showed that these effectors can modulate the shape of the FWJ in order to structurally optimise the ligand/DNA association (induced-fit). Regarding the way small molecules interact with finally, the X-ray structure of C6 in interaction with a full FWJ resulting from the self-assembly of the d(CCGGTACCGG) sequence was successfully solved and refined (Figure 5B) (118). This clearly defined binding mode affirmed the suitability of the central cavity of FWJs to accommodate close contacts with dedicated ligands. (FIGURE, 14, DNA Junction)




FWJs (Figure 3B), the first insights were obtained through the ligand-induced dimerization of a short, 6-nucleotide (6- nt) duplex. In this study (114), incubation of the self- complementary d(CGTACG) sequence, or the closely related d(CG[5-BrU]ACG), with acridines (e.g. DACA, 9- amino-DACA, Figures 3B and 5A) (114) and phenazine.(115) derivatives provided an asymmetric unit in which the terminal C of one strand invades the second helix at the lig- and binding site, therefore creating a cavity in which two acridines nestle in between four base pairs (Figure 5A). We thus designed dimeric derivatives of DACA (linked through 1,6-diaminohexane or 1,8-diaminooctane linkers, named C6 and C8, respectively, Figures 3B and 5B) as possible bisintercalators and determined two types of X-ray structures with d(CGTACG): a structure in which, behaving similarly to its monomeric counterpart (see above), C8 induces a FWJ-like assembly on the basis of a terminal C exchange and creates a H-bond with the residue G6 (Figure 22); (116) and a structure in which C6 cross links two separate duplexes, each of its acridine units being intercalated in between two CG base pairs of a given duplex (Figure-15-X DNA structure) (117).



. In this example, the acridine units cause two A residues (A6) at the central TA step of the crossover strands to flip out to generate the ligand binding site in which both a long H-bond (between the DACA side chain and the residue C7) and stacking interactions (in between a T and a C) with surrounding nucleobases are created. Later, it was demonstrated that DACA derivatives were also able to induce the formation of FWJs (119); however, these studies, though elegant and insightful, were limited to structural investigations only, owing to the known tendency of acridine derivatives to intercalate within duplexes (120). Their use in cell-based assays would have been troublesome because of their strong B-DNA interaction, which would have blurred the relevance of FWJs as therapeutic target: indeed, it would have been impossible to discriminate the origins of the cellular effects observed between those originating in B-DNA intercalation (the most likely event) and those originating in FWJ interaction (the less likely event). This is mostly due to the fact that these ligands do not target the unique structural component of FWJs (i.e. the central cavity), but instead bind to the duplex arms at the proximity of the cavity, which makes specific interaction unattainable. One possibility would have been to structurally fine-tune acridines to preclude intercalation in a manner reminiscent of what was done with G4 ligands, which led to the design of the 3,6,9-trisubstituted acridine BRACO-19 (121). Another possibility was to target the central cavity of FWJs; as discussed further below, this was done with a series of short peptides but without firm structural characterization of their FWJ binding mode. As with the original Holliday junction structure, which was a serendipitous discovery while studying DNA mismatches, a recent mismatch study also uncovered junction formation (122). A potent DNA-binding compound triaminotriazine-acridine conjugate (Z1, Figure 3B) functions by targeting T:T mismatches in CTG trinucleotide repeats that are responsible for neurological diseases such as myotonic dystrophy type 1, but its binding mechanism remains unclear. The crystal structure of this ligand was solved in a complex with DNA containing three consecutive CTG repeats with three T:T mismatches. Surprisingly, direct intercalation of two Z1 molecules at both ends of the CTG repeats induced T base flipping (T4), a H-bond between Z1 and a T (T10) and DNA backbone deformation to form a four-way junction (Figure 5C). The core of the complex

unexpectedly adopts a U-shaped head-to-head topology to form a crossover of each chain at the junction site. The crossover junction is held together by two stacked G:C pairs at the central core that rotate with respect to each other in an X-shape to form two nonplanar minor-groove-aligned G:C:G:C tetrads. Two stacked G:C pairs on both sides of the central core are involved in the formation of pseudo- continuous duplex DNA. However, and again, these studies were limited to structural investigations only owing to the lack of information concerning the specificity of Z1 for FWJs that, combined with the known health-threatening nature of triazines (notably widely used as herbicides) (123), is not the best guarantee of a bright future for this series of compounds.



(FIG-16 PDB,H-BONDING)

E.3. The relevance of FWJ in cells

Although the central position of HJs in HR has been firmly established for decades (91), it is only recently that they were visualized in cells (124). While HR is only one of two major pathways leading to double strand DNA break (DSB) re- pair in mammalian cells, along with non-homologous end joining (NHEJ) (Figure 6) (125), it is indispensable in lower organisms (bacteria, yeasts) for ensuring DNA transfer and adapting to evolution (natural selection) (126). It is therefore unsurprising that a vast body of research has been dedicated to understanding the roles of HJ/FWJ in

yeasts and bacteria. These efforts have led to the discovery of the RuvABC complex that operates at HJs in prokaryotes (*Escherichia coli*) in a sequential manner: RuvA binds to HJs and targets RuvB to the junction, both RuvA and RuvB (RuvAB) promote branch migration and RuvC resolves the junction (127). An engineered synthetic protein RuvCDefGFP was recently used to investigate HJs in cells der [Fe2L3]4+) was misleadingly ascribed to RFs (101,137), while the fine structural details of RFs indicate that it is in- deed a Y-shaped structure but made of unpaired sequences at the junction, unlike TWJs (170). Second, these first cellular investigations failed in providing convincing results, and the ability of [Fe2L3]4+ to interact with DNA in cells was even questioned (189). Third, the very nature of [Fe2L3]4+ made these investigations irrelevant owing to the ability of this supramolecular complex to interact with other DNA structures including the major grooves of B-DNA (191) and G4s (122,143). Therefore, this prototype was invaluable to uncover and accurately characterize a completely new DNA binding mode (with a molecule nestling within the central cavity of a TWJ) but was not ideally suited for chemical biology investigations. A very interesting observation, however, was that the closely related cylinder [Ru2L3]4+ was able to inhibit DNA transactions by preventing polymerase processivity; (194) this laid the basis for investigating whether TWJs might fold during DNA transactions in cells, more particularly at replication sites in the nucleus. To this end, co-localization studies were performed with a fluorescently labelled Fe(II) helicate (TAMRA-LLD, Figure 8B) and PCNA (proliferating cell nuclear antigen, a component of the replication machinery) fused to the green fluorescent protein (GFP) in





FIGURE-17, Synthesis of new DNA.+

HeLa cells (177). The collected images showed well-defined common foci, indicating that TWJs might fold transiently during DNA replication, in the vicinity of the replisome, and be trapped by ad hoc ligands. Similar co-localization studies were recently performed with a TWJ probe comprising a central, C3-symmetrical florigenic template (1,3,5-tristyrylbenzene) surrounded by three peptidic arms designed to interact with the three duplex arms of the TWJs (AT-hooks), thus found to preferentially accumulate in permeabilized cells where PCNA-GFP accumulates (195). However, the relevance of these results needs to be substantiated by a clear demonstration of the selectivity of used ligands for TWJs, as off-target effects cannot be ruled out on the basis of the currently available in vitro data. Studies were also performed to investigate whether TWJ ligands trigger DNA damage in dividing cells. This was firmly established via the immune detection of γ H2AX by both optical imaging and flow cytometry: after a thorough characterization of their TWJ-interacting properties in vitro (affinity and specificity via a panel of different techniques), two azacryptands (TrisPOB, TrisNP) were studied in cells and shown to trigger an accumulation of DNA strand breaks (and particularly DSBs) (Figures 3C, 8C and 9) (155,156). When combined with the established ability of TWJ ligands to prevent polymerase activity in vitro (194), these results thus provided a strong rationale for a mechanistic model in which ligand-stabilized TWJs act as road-blocks that hamper proper processivity of DNA-related enzymes, slowing or even stopping their motion along the genomic duplex, which is recognized as a DNA damage and trigger the DDR and repair machineries. We further exploited this model by using drug combinations in which TWJ ligands were used to induce DNA damage and DNA repair inhibitors to act synergistically with them, in an approach referred to as chemically induced synthetic lethality (176). In eukaryotic cells, DSBs can be repaired by either HR (vide supra) or non-homologous end joining (NHEJ). (Figure 6). The former relies on a broad array of protein effectors including RAD51 (which binds to single-stranded DNA, searches for sequence homology and favours strand exchange), and the kinases ATM and ATR (which bind to DSBs and stalled RFs, respectively); the latter also involves multiple processing enzymes, including kinases and ligases (e.g. DNA-PK and Lig4, respectively) (58,59,125). The antiproliferative activity of the TWJ ligands TrisPOB and TrisNP was found to be quite efficiently potentiated when combined with inhibitors of DNA-PK (NU-7441), ATM (KU-55933) and RAD51 (B02) (155,156), confirming that the cellular activity of TWJ ligands relies on the induction of strongly genotoxic DSBs (Figure 9). Interestingly, a synergy was also obtained with the Top2 inhibitor BNS-22: Top2 proteins resolve DNA topological stress (197) but are also involved in the recognition of alternative DNA structures and the formation of DSBs at these sites (198). Top2 also participates in the cleavage of hairpin structures formed from α -satellite sequences in vitro (199), which are centromeric regions known to be highly repetitive (200) and to fold into secondary structures (201). This synergy, confirmed by cytotoxicity assessments and γ H2AX labelling, thus


implies that Top2 inhibition favours TWJ formation, which was further demonstrated unambiguous interpretation of cellular outcomes. To confirm this interpretation, we showed by



Figur-18, PDB,TWJ

by bio orthogonal chemistry using the in situ clickable TWJ ligand TrisNP- α , Figure 3C) (156), which highlight the increase of the TWJ landscape (TrisNP- α labelling) upon Top2 inhibition (Figure 9). This opens brand new therapeutic opportunities, notably to treat cancers resistant to Top2 poisons. As above, though comprehensive from a molecular and cellular biology point of view, these studies suffer from the fact that used TWJ ligands display a unneglectable affinity for G4s. It was demonstrated in vitro that they display a preferential affinity for TWJ (i.e. in competitive setups where both TWJ and G4 are mixed, the ligands interact solely with TWJ) but this selectivity was not satisfying enough for an optical imaging that there is no overlaps between TWJ sites labelled with TrisNP- α (in situ click chemistry (182) with AF594-azide) and G4 sites labelled with the G4-specific antibody BG4 (35). These results are highly convincing but they are still not strong enough to unequivocally dispel doubts about the actual origins of the cellular effects monitored upon cell incubation with bona fide TWJ ligands. What the field now needs is a truly specific TWJ ligand; in light of the wealth of promising data described above, we can wager that a substantial research effort is currently being invested to identify the impatiently awaited game-changing TWJ ligand (128). RuvCDefGFP is a catalytically defective (Def) RuvC fused to green fluorescent protein (GFP); it was used to both map HJs in *E. coli* by HJ-ChIP-seq (using the anti- RuvC antibody), which demonstrated the accumulation of HJs near DSB sites, and visualize HJs via live-cell imaging, with a distribution correlated with homology-directed DSB repair, notably at single-stranded gaps.



These compelling results thus lend further credence to value of targeting HJs in bacteria by small molecules. The short hexapeptides developed by Anca M. Segall and co-workers were among the first reported HJ-ligands. It was first demonstrated that WKHYN Y (Trp-Lys-His-Tyr-Asn- Tyr) target HJs in vitro and inhibits its resolution by the re- combination proteins integration host factor (IHF, a hetero-dimeric protein that binds to and bends DNA and RNA.



(FIGURE-19 FWJ OF DNA)

F. CONCLUSIONANDFUTUREDIRECTIONS

Targeting higher-order DNA structures with ad hoc ligands for **chemical biology and/or medicinal chemistry purposes is now a commonly accepted strategy**, undoubtedly as a consequence of the wealth of data accumulated about G4-DNA (68,69), the first-in-class example of a biologically relevant alternative DNA structure. While DNA junctions were discovered concomitantly with G4s (as indicated above, their basic structural unit was solved in 1962 (23) but their biological relevance was only discussed in the late



1980s) (24,178,181), the investigations aiming at confirming the existence of DNA junctions in human cells, scrutinizing their functional relevance and establishing the re-liability of the therapeutic strategies based on their targeting with small molecules still a away behind that of G4s. This might be attributed to several factors: first and fore-most, right after the pioneering report by Stephen Neidle, Lawrence H. Hurley and co-workers on a small molecule able to interact with a G4 (in the aim of indirectly inhibiting telomerase via the sequestration of its telomeric substrate under a form that is not recognized by the enzyme) (175), hundreds of G4 ligands have been synthesized and studied (75,168). This incredible enthusiasm has provided a strong impetus for the discovery of truly specific ligands (e.g. PhenDC3 (151), PDS) (140) which have soon become invaluable molecular tools to decipher G4 biology in a highly accurate manner (159). The DNA junction field has not experienced such a keen interest, presumably because the biological relevance of DNA junctions is still poorly understood. Also, the search for genomic G4 sites via in silico techniques (e.g. Quad Parser (180), G4hunter (171), etc.) was straightforward thanks to the very nature of G4-forming sequences (example of fused algorithm: $d(G_3+N_{1-7}G_3+N_{1-7}G_3+N_{1-7}G_3+)$) (162). They have provided strong arguments about the prevalence of G4s in the human genome, which was soon connected to wide spread functional relevance. The nature of the DNA junction-forming sequences (direct or inverted sequence repeats, and note easily identifiable motif repeats such

as GGG triplets) make them more difficult to be reliably predicted at a genome-wide scale (although some laudable attempts have been made, such as IR finder (153), palindrome analyzer (144), etc.). Again, this has contributed to some-what dampen enthusiasm for the search of genomic DNA junction-forming sites. Finally the challenge of identifying genomic G4 sites by ChIP seq like techniques (such as G4ChIP-seq) (50) was met, thanks to the development of the G4-specific antibody BG4(35), and no similar antibody exists in the DNA junction field, which makes both their identification (ChIP) and visualization (immune fluorescence) challenging and regularly questioned. Despite the difficulties, the aforementioned efforts have started to pay off, but the prevalence of putative DNA junction-forming sequences described above (37,41) combined with the lack of fine details regarding DNA junction biology (which originates in the lack of reliable molecular tools) explain why this chemical biology quest is still in its infancy. Massive efforts must now be invested to keep on developing tools and technologies to interrogate and manipulate DNA junctions in a functional cellular context. The next steps will thus be to (i) identify truly specific ligands for DNA junctions, in order to establish a reliable link between junction interaction in cells and the cellular outcomes monitored; (ii) create and/or optimize in vitro screening as says to blind screen commercially available chemo libraries in order to expand the portfolio of DNA junction ligand candidates far beyond rational design; (iii) develop on the basis of identified promising scaffolds multivalent molecular tools (bearing for instance an alkynes appendage that could be manipulated in a bio orthogonal manner in cells) to identify these sequences they interact with (direct repeats? Inverted repeats? other?) and the protein as associated combining both sequencing (bioinformatics tools will have to be optimized as well) and proteomics. Of note, the identification of DNA junction-binding proteins will be a very important step as they are the cellular effect or by which the response to junction stabilization by ad hoc ligands is mediated; while hundreds of G4-binding proteins are now known (175), only a handful of junction-binding proteins have been reported to date (e.g. RuvABC and RecG, vide supra); (iv) produce DNA junction-specific antibodies for both immune precipitation and immune detection purposes, and (v) develop cellular and small animal models to assess the properties of identified candidates in a standardized manner. The ultimate goal of the seen investigations will be to rapidly provide a proof-of-concept that DNA junction-targeting molecules can be considered as key players in the field of the therapeutic agents, to validate all the necessary pre-clinical milestones in a reliable manner in the aim of reaching the clinical stage rapidly and confidently. Without a doubt, the chemical biology investigations will to major advances in research on this new class of therapeutic targets, a momentum that will contribute to both better understand the biology of DNA junctions (which will

find applications in diverse the rapeutic areas such as cancers (62), neuro pathologies(165)and in factious diseases) and unravel the fascinating structural and functional diversity of DNA.

Anew Drug Design strategy in the light of Molecular Hybridization Concept of DNA/RNA small

molecules attachments: Molecular hybridization of nucleic acids is the process in which two single-stranded nucleic acid molecules with complementary base sequences form a double-stranded nucleic acid molecule. Nucleic acid hybridization technology is a fundamental tool in molecular biology, and has been applied in various fields such as detection of gene expression, screening specific clone from DNA or genomic library, determining the location of a gene in chromosome and diagnosis of diseases like property for eg grapheme or glue like bio material from spider or even polymer can bind rapid growth of cell for its binding nature at micro level or can trap bacterial or viral growth by trapping within Net like structure. The idea of Quantum Dots may be implied to identify such net as drug to separate from diseases infected Zone. Sometime electrification or by application of Radioactivity through this net may reduce harmful diseases spreading.

Molecular hybridization a useful tool in the design, trapping of new generation drug prototypes using the sequencing of Nucleic acids for a particular patient. Molecular hybridization is a new concept in drug design and development based on the combination of pharmacophoric moieties of different bioactive substances to produce a new hybrid compound with improved affinity and efficacy, when compared to the parent drugs. Additionally, this strategy can result in compounds presenting modified selectivity profile, different and/or dual modes of action and reduced undesired side effects. So, in this paper, we described several examples of different strategies for drug design, discovery and pharmaco modulation focused on new innovative hybrid compounds presenting analgesic, anti-inflammatory, platelet anti-aggregating, anti-infectious, anti cancer, cardio- and neuro active properties.

By this molecular hybridization concept in the field of genetic engineering and as well as molecular biology, formation of a partially or wholly complementary nucleic acid duplex as association of single strands, usually between DNA and RNA strands (previously associated or un associated DNA , RNA strands.). These are used to detect an isolated specific genetically initiated sequences as measured sequencing homology, or define other characteristics of one or both strands. If we can detect the particular cause of critical disease like Parkinson, Cancer or AIDS for a particular patient. We can synthesis the new drug design for that patient to treat them for complete cure in this molecular hybridisation concept. So this is a new generation concept for developing drug as well as the cause of the

particular diseases for a particular patient. Not only that by fusing more than one drugs structure components by Molecular hybridisation concept we can make a single drug for a patient with multiple affected diseases using computer simulation more modern method in the field of medicinal chemistry. The idea will show us to find the way of sustainable health and immortality in future.

REFERENCE

1. Hoshika,S., Leal,N.A., Kim,M.-J., Kim,M.-S., Karalkar,N.B., Kim,H.-J., Bates,A.M., Watkins,N.E., SantaLucia,H.A., Meyer,A.J. et al. (2019) Hachimoji DNA and RNA: a genetic system with eight building blocks. *Science*, 363, 884–887.
2. Kirnos,M.D., Khudyakov,I.Y., Alexandrushkina,N.I. and Vanyushin,B.F. (1977) 2-Aminoadenine is an adenine substituting for a base in S-2L cyanophage DNA. *Nature*, 270, 369–370.
3. Pezo,V., Jaziri,F., Bourguignon,P.-Y., Louis,D., Jacobs-Sera,D., Rozenski,J., Pochet,S., Herdewijn,P., Hatfull,G.F., Kaminski,P.-A. et al. (2021) Noncanonical DNA polymerization by amino adenine-based siphoviruses. *Science*, 372, 520–524.
4. Sleiman,D., Garcia,P.S., Lagune,M., Loc'h,J., Haouz,A., Taib,N., Rothlisberger,P., Gribaldo,S., Marliére,P. and Kaminski,P.A. (2021) A third purine biosynthetic pathway encoded by amino adenine-based viral DNA genomes. *Science*, 372, 516–520.
5. Zhou,Y., Xu,X., Wei,Y., Cheng,Y., Guo,Y., Khudyakov,I., Liu,F., He,P., Song,Z., Li,Z. et al. (2021) A widespread pathway for substitution of adenine by diaminopurine in phage genomes. *Science*, 372, 512–516.
6. Ghosh,A. and Bansal,M. (2003) A glossary of DNA structures from a to Z. *Acta Crystallogr. D: Biol. Crystallogr.*, 59, 620–626.
7. Franklin,R.E. and Gosling,R.G. (1953) The structure of sodium thymonucleate fibres. I. The influence of water content. *Acta Crystallogr.*, 6, 673–677.
8. Franklin,R.E. and Gosling,R.G. (1953) Evidence for 2-chain helix in crystalline structure of sodium deoxyribonucleate. *Nature*, 172, 156–157.
9. Franklin,R.E. and Gosling,R.G. (1953) Molecular configuration in sodium thymonucleate. *Nature*, 171, 740–741.
10. Elkin,L.O. (2003) Rosalind franklin and the double helix. *Physics Today*, 56, 42–48.
11. Ravichandran,S., Subramani,V.K. and Kim,K.K. (2019) Z-DNA in the genome: from structure to disease. *Biophys. Rev.*, 11, 383–387.
12. Crick,F.H. (1958) On protein synthesis. *Symp. Soc. Exp. Biol.*, 12, 138–163.
13. Crick,F. (1970) Central dogma of molecular biology. *Nature*, 227, 561.
14. Wilkins,M.H.F., Stokes,A.R. and Wilson,H.R. (1953) Molecular structure of nucleic acids: molecular structure of deoxypentose nucleic acids. *Nature*, 171, 738–740.
15. Dalla Pozza,M., Abdullrahman,A., Cardin,C.J., Gasser,G. and Hall,J.P. (2022) Three's a crowd – stabilisation, structure, and applications of DNA triplexes. *Chem. Sci.*, 13, 10193–10215.
16. Htun,H. and Dahlberg,J.E. (1989) Topology and formation of triple-stranded H-DNA. *Science*, 243, 1571–1576.
17. Felsenfeld,G., Davies,D.R. and Rich,A. (1957) Formation of a three-stranded polynucleotide molecule. *J. Am. Chem. Soc.*, 79, 2023–2024.
18. Lee,J.S., Johnson,D.A. and Morgan,A.R. (1979) Complexes formed by (pyrimidine)_n (purine)_n DNAs on lowering the pH are

three-stranded. *Nucleic Acids Res.*, 6, 3073–3091.

18. Gellert, M., Lipsett, M.N. and Davies, R.D. (1962) Helix formation by guanylic acid. *Proc. Natl. Acad. Sci. U.S.A.*, 77, 6468–6472.
19. Lilley, D.M. (1980) The inverted repeat as a recognizable structural feature in supercoiled DNA molecules. *Proc. Natl. Acad. Sci. U.S.A.*, 77, 6468–6472.
20. Panayotatos, N. and Wells, R.D. (1981) Cruciform structures in supercoiled DNA. *Nature*, 289, 466–470.
21. Pohl, F.M. (1967) Ein modell der DNS-Struktur. *Naturwissenschaften*, 54, 616–616.
22. Wang, A.H.J., Quigley, G.J., Kolpak, F.J., Crawford, J.L., van Boom, J.H., van der Marel, G. and Rich, A. (1979) Molecular structure of a left-handed double helical DNA fragment at atomic resolution. *Nature*, 282, 680–686.
23. Sivakova, S. and Rowan, S.J. (2005) Nucleobases as supramolecular motifs. *Chem. Soc. Rev.*, 34, 9–21.
24. Hoogsteen, K. (1959) The structure of crystals containing a hydrogen-bonded complex of 1-methylthymine and 9-methyladenine. *Acta Crystallogr.*, 12, 822–823.
25. Hoogsteen, K.R. (1963) The crystal and molecular structure of a hydrogen-bonded complex between 1-methylthymine and 9-methyladenine. *Acta Crystallogr.*, 16, 907–916.
26. Arnott, S. and Bond, P.J. (1973) Structures for Poly(U).poly(A).poly(U) triple stranded polynucleotides. *Nat. New Biol.*, 244, 99–101.
27. Biffi, G., Tannahill, D., McCafferty, J. and Balasubramanian, S. (2013) Quantitative visualization of DNA G-quadruplex structures in human cells. *Nat. Chem.*, 5, 182–186.
28. Di Antonio, M., Ponjavic, A., Radzevicius, A., Ranasinghe, R.T., Catalano, M., Zhang, X., Shen, J., Needham, L.-M., Lee, S.F., Klennerman, D. et al. (2020) Single-molecule visualization of DNA G-quadruplex formation in live cells. *Nat. Chem.*, 12, 832–837.
29. Treangen, T.J. and Salzberg, S.L. (2012) Repetitive DNA and next-generation sequencing: computational challenges and solutions. *Nat. Rev. Genet.*, 13, 36–46.
30. Wang, G. and Vasquez, K.M. (2006) Non-B DNA structure-induced genetic instability. *Mutat. Res.*, 598, 103–119.
31. Pearson, C.E. and Sinden, R.R. (1996) Alternative structures in duplex DNA formed within the trinucleotide repeats of the myotonic dystrophy and fragile x loci. *Biochem.*, 35, 5041–5053.
32. Wells, R.D. (2007) Non-B DNA conformations, mutagenesis and disease. *Trends Biochem. Sci.*, 32, 271–278.
33. Georgakopoulos-Soares, I., Morganella, S., Jain, N., Hemberg, M. and Nik-Zainal, S. (2018) Noncanonical secondary structures arising from non-B DNA motifs are determinants of mutagenesis. *Genome Res.*, 28, 1264–1271.
34. Murat, P., Guilbaud, G. and Sale, J.E. (2020) DNA polymerase stalling at structured DNA constrains the expansion of short tandem repeats. *Genome Biol.*, 21, 209.
35. Singleton, M.R., Dillingham, M.S. and Wigley, D.B. (2007) Structure and mechanism of helicases and nucleic acid translocases. *Annu. Rev. Biochem.*, 76, 23–50.
36. Chambers, V.S., Marsico, G., Boutell, J.M., Di Antonio, M., Smith, G.P. and Balasubramanian, S. (2015) High-throughput sequencing of DNA G-quadruplex structures in the human genome. *Nat. Biotechnol.*, 33, 877–881.
37. Pen˜a Martinez, C.D., Zeraati, M., Rouet, R., Mazigi, O., Gloss, B., Chan, C.-L., Bryan, T.M., Smith, N.M., Dinger, M.E., Kummerfeld, S. et al. (2022) Human genomic DNA is widely interspersed with i-motif structures. *bioRxiv* doi: <https://doi.org/10.1101/2022.04.14.488274>, 14 April 2022, preprint: not peer reviewed.
38. Marsico, G., Chambers, V.S., Sahakyan, A.B., McCauley, P., Boutell, J.M., Antonio, M.D. and Balasubramanian, S. (2019) Whole genome experimental maps of DNA G-quadruplexes in multiple species. *Nucleic Acids Res.*, 47, 3862–3874.
39. Feng, Y., Tao, S., Zhang, P., Rota Sperti, F., Liu, G., Cheng, X., Zhang, T., Yu, H., Wang, X., Chen, C. et al. (2022)

Epigenomic features of DNA G-quadruplexes and their roles in regulating rice gene transcription. *Plant Physiol.*, 188, 1632–1648

40. Ma,X., Feng,Y., Yang,Y., Li,X., Shi,Y., Tao,S., Cheng,X., Huang,J., Wang,X., Chen,C. et al. (2022) Genome-wide characterization of i-motifs and their potential roles in the stability and evolution of transposable elements in rice. *Nucleic Acids Res.*, 50, 3226–3238.
41. Li,M., Tian,R., Monchaud,D. and Zhang,W. (2022) Omics studies of DNA G-/C-quadruplexes in plants. *Trends Genet.*, 38, 999–1002.
42. Hañsel-Hertsch,R., Beraldi,D., Lensing,S.V., Marsico,G., Zyner,K., Parry,A., Di Antonio,M., Pike,J., Kimura,H. and Narita,M. (2016) G-quadruplex structures mark human regulatory chromatin. *Nat. Genet.*, 48, 1267–1272.
43. Kouzine,F., Wojtowicz,D., Baranello,L., Yamane,A., Nelson,S., Resch,W., Kieffer-Kwon,K.-R., Benham,C.J., Casellas,R., Przytycka,T.M. et al. (2017) Permanganate/S1 nuclease footprinting reveals Non-B DNA structures with regulatory potential across a mammalian genome. *Cell Syst.*, 4, 344–356.
44. van Wietmarschen,N., Sridharan,S., Nathan,W.J., Tubbs,A., Chan,E.M., Callen,E., Wu,W., Belinky,F., Tripathi,V., Wong,N. et al. (2020) Repeat expansions confer WRN dependence in microsatellite-unstable cancers. *Nature*, 586, 292–298.
45. Matos-Rodrigues,G., van Wietmarschen,N., Wu,W., Tripathi,V., Koussa,N.C., Pavani,R., Nathan,W.J., Callen,E., Belinky,F., Mohammed,A. et al. (2022) S1-END-seq reveals DNA secondary structures in human cells. *Mol. Cell*, 82, 3538–3552.
46. Shah,K.A., Shishkin,A.A., Voineagu,I., Pavlov,Y.I., Shcherbakova,P.V. and Mirkin,S.M. (2012) Role of DNA polymerases in repeat-mediated genome instability. *Cell Rep.*, 2, 1088–1095.
47. Shah,K.A. and Mirkin,S.M. (2015) The hidden side of unstable DNA repeats: mutagenesis at a distance. *DNA Repair*, 32, 106–112.
48. Wang,G. and Vasquez,K.M. (2014) Impact of alternative DNA structures on DNA damage, DNA repair, and genetic instability. *DNA Repair*, 19, 143–151.
49. Jackson,S.P. and Bartek,J. (2009) The DNA-damage response in human biology and disease. *Nature*, 461, 1071–1078.
50. Ciccio,A. and Elledge,S.J. (2010) The DNA damage response: making it safe to play with knives. *Mol. Cell*, 40, 179–204.
51. Blackford,A.N. and Jackson,S.P. (2017) ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. *Mol. Cell*, 66, 801–817.
52. Mirkin,E.V. and Mirkin,S.M. (2007) Replication fork stalling at natural impediments. *Microbiol. Mol. Biol. Rev.*, 71, 13–35.
53. Belotserkovskii,B.P., Mirkin,S.M. and Hanawalt,P.C. (2013) DNA sequences that interfere with transcription: implications for genome function and stability. *Chem. Rev.*, 113, 8620–8637.
54. Zell,J., Rota Sperti,F., Britton,S. and Monchaud,D. (2021) DNA folds threaten genetic stability and can be leveraged for chemotherapy. *RSC Chem. Biol.*, 2, 47–76.
55. Kaushal,S. and Freudenreich,C.H. (2019) The role of fork stalling and DNA structures in causing chromosome fragility. *Genes Chromosomes Cancer*, 58, 270–283.
56. del Mundo,I.M., Vasquez,K.M. and Wang,G. (2019) Modulation of DNA structure formation using small molecules. *Biochim. Biophys. Acta - Mol. Cell Res.*, 1866, 118539.
57. Roos,W.P., Thomas,A.D. and Kaina,B. (2016) DNA damage and the balance between survival and death in cancer

biology. *Nat. Rev. Cancer*, 16, 20–33.

58. Hilton,J., Gelmon,K., Bedard,P.L., Tu,D., Xu,H., Tinker,A.V., Goodwin,R., Laurie,S.A., Jonker,D., Hansen,A.R. et al. (2022) Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies. *Nat. Commun.*, 13, 3607.
59. Burge,S., Parkinson,G.N., Hazel,P., Todd,A.K. and Neidle,S. (2006) Quadruplex DNA: sequence, topology and structure. *Nucleic Acids Res.*, 34, 5402–5415.
60. Rhodes,D. and Lipps,H.J. (2015) G-quadruplexes and their regulatory roles in biology. *Nucleic Acids Res.*, 43, 8627–8637.
61. Varshney,D., Spiegel,J., Zyner,K., Tannahill,D. and Balasubramanian,S. (2020) The regulation and functions of DNA and RNA G-quadruplexes. *Nat. Rev. Mol. Cell Biol.*, 21, 459–474.
62. Lilley,D.M. (2000) Structures of helical junctions in nucleic acids. *Q. Rev. Biophys.*, 33, 109–159.
63. Altona,C. (1996) Classification of nucleic acid junctions. *J. Mol. Biol.*, 263, 56.
64. Monchaud,D. and Teulade-Fichou,M.-P. (2008) A hitchhiker’s guide to G-quadruplex ligands. *Org. Biomol. Chem.*, 6, 627–636.
65. Le,T.V.T., Han,S., Chae,J. and Park,H.-J. (2012) G-Quadruplex binding ligands: from naturally occurring to rationally designed molecules. *Curr. Pharm. Des.*, 18, 1948–1972.
66. Neidle,S. (2016) Quadruplex nucleic acids as novel therapeutic targets. *J. Med. Chem.*, 59, 5987–6011.
67. Spiegel,J., Adhikari,S. and Balasubramanian,S. (2020) The structure and function of DNA G-quadruplexes. *Trends Chem.*, 2, 123–136.
68. Kosiol,N., Juranek,S., Brossart,P., Heine,A. and Paeschke,K. (2021) G-quadruplexes: a promising target for cancer therapy. *Mol. Cancer*, 20, 40.
69. Ivens,E., Cominetti,M.M.D. and Searcey,M. (2022) Junctions in DNA: underexplored targets for therapeutic intervention. *Bioorg. Med. Chem.*, 69, 116897.
70. Lu,M., Guo,Q. and Kallenbach,N.R. (1992) Interaction of drugs with branched DNA structures. *Crit. Rev. Biochem. Mol. Biol.*, 27, 157–190.
71. Marky,L.A., Kallenbach,N.R., McDonough,K.A., Seeman,N.C. and Breslauer,K.J. (1987) The melting behavior of a DNA junction structure: a calorimetric and spectroscopic study. *Biopolymers*, 26, 1621–1634.
72. Seeman,N.C., Chen,J.H. and Kallenbach,N.R. (1989) Gel electrophoretic analysis of DNA branched junctions. *Electrophoresis*, 10, 345–354.
73. Guo,Q., Seeman,N.C. and Kallenbach,N.R. (1989) Site-specific interaction of intercalating drugs with a branched DNA molecule. *Biochem.*, 28, 2355–2359.
74. Churchill,M., Tullius,T.D., Kallenbach,N.R. and Seeman,N.C. (1988) A holliday recombination intermediate is twofold symmetric. *Proc. Natl. Acad. Sci. U.S.A.*, 85, 4653–4656.
75. Lu,M., Guo,Q. and Kallenbach,N.R. (1993) Thermodynamics of G-tetraplex formation by telomeric DNAs. *Biochem.*, 32, 598–601.
76. Lu,M., Guo,Q. and Kallenbach,N.R. (1992) Structure and stability of sodium and potassium complexes of dT4G4 and dT4G4T. *Biochem.*, 31, 2455–2459.
77. Hernandez,L.I., Zhong,M., Courtney,S.H., Marky,L.A. and Kallenbach,N.R. (1994) Equilibrium analysis of ethidium binding to DNA containing base mismatches and branches. *Biochem.*, 33, 13140–13146.
78. Lu,M., Guo,Q., Seeman,N.C. and Kallenbach,N.R. (1990) Drug binding by branched DNA: selective interaction of

the dye stains-all with an immobile junction. *Biochem.*, 29, 3407–3412.

79. Lu,M., Guo,Q., Pasternack,R.F., Wink,D.J., Seeman,N.C. and Kallenbach,N.R. (1990) Drug binding by branched DNA: selective interaction of tetrapyridyl porphyrins with an immobile junction. *Biochem.*, 29, 1614–1624.
80. Guo,Q., Lu,M., Churchill,M., Tullius,T. and Kallenbach,N.R. (1990) Asymmetric structure of a three-arm DNA junction. *Biochem.*, 29, 10927–10934.
81. Guo,Q., Lu,M., Marky,L.A. and Kallenbach,N.R. (1992) Interaction of the dye ethidium bromide with DNA containing guanine repeats. *Biochem.*, 31, 2451–2455.
82. Liu,Y. and West,S.C. (2004) Happy hollidays: 40th anniversary of the holliday junction. *Nat. Rev. Mol. Cell Biol.*, 5, 937–944.
83. Gall,J.G. (1954) Lampbrush chromosomes from oocyte nuclei of the newt. *J. Morphol.*, 94, 283–351.
84. Cooper,J.P. and Hagerman,P.J. (1987) Gel electrophoretic analysis of the geometry of a DNA four-way junction. *J. Mol. Biol.*, 198, 711–719.
85. Duckett,D.R., Murchie,A.I., Diekmann,S., von Kitzing,E., Kemper,B. and Lilley,D.M. (1988) The structure of the holliday junction, and its resolution. *Cell*, 55, 79–89.
86. Gough,G.W. and Lilley,D.M. (1985) DNA bending induced by cruciform formation. *Nature*, 313, 154–156.
87. Cooper,J.P. and Hagerman,P.J. (1990) Analysis of fluorescence energy transfer in duplex and branched DNA molecules. *Biochem.*, 29, 9261–9268.
88. Murchie,A.I., Clegg,R.M., von Krtzing,E., Duckett,D.R., Diekmann,S. and Lilley,D.M. (1989) Fluorescence energy transfer shows that the four-way DNA junction is a right-handed cross of antiparallel molecules. *Nature*, 341, 763–766
89. Pikkemaat,J.A., van den Elst,H., van Boom,J.H. and Altona,C. (1994) NMR studies and conformational analysis of a DNA four-way junction formed in a linear synthetic oligonucleotide. *Biochem.*, 33, 14896–14907.
90. Potter,H. and Dressler,D. (1977) On the mechanism of genetic recombination: the maturation of recombination intermediates. *Proc. Natl. Acad. Sci. U.S.A.*, 74, 4168–4172.
91. Mao,C., Sun,W. and Seeman,N.C. (1999) Designed two-dimensional DNA holliday junction arrays visualized by atomic force microscopy. *J. Am. Chem. Soc.*, 121, 5437–5443.
92. Lilley,D.M. and Norman,D.G. (1999) The holliday junction is finally seen with crystal clarity. *Nat. Struct. Biol.*, 6, 897–899.
93. Ortiz-Lombard'ia,M., Gonza'lez,A., Eritja,R., Aymam'ı,J., Azor'ın,F. and Coll,M. (1999) Crystal structure of a DNA holliday junction. *Nat. Struct. Biol.*, 6, 913–917.
94. Eichman,B.F., Vargason,J.M., Mooers,B.H. and Ho,P.S. (2000) The holliday junction in an inverted repeat DNA sequence: sequence effects on the structure of four-way junctions. *Proc. Natl. Acad. Sci. U.S.A.*, 97, 3971–3976.
95. Roe,S.M., Barlow,T., Brown,T., Oram,M., Keeley,A., Tsaneva,I.R. and Pearl,L.H. (1998) Crystal structure of an octameric ruvA–Holliday junction complex. *Mol. Cell*, 2, 361–372.
96. Hargreaves,D., Rice,D.W., Sedelnikova,S.E., Artymiuk,P.J., Lloyd,R.G. and Rafferty,J.B. (1998) Crystal structure of *e. coli* RuvA with bound DNA holliday junction at 6 Å resolution. *Nat. Struct. Biol.*, 5, 441–446.
97. Gopaul,D.N., Guo,F. and Van Duyne,G.D. (1998) Structure of the holliday junction intermediate in Cre–loxP site-specific recombination. *EMBO J.*, 17, 4175–4187.
98. Lilley,D.M. (2017) Holliday junction-resolving enzymes—structures and mechanisms. *FEBS Lett.*, 591, 1073–1082.
99. Hays,F.A., Teegarden,A., Jones,Z.J.R., Harms,M., Raup,D., Watson,J., Cavaliere,E. and Ho,P.S. (2005) How sequence defines structure: a crystallographic map of DNA structure and conformation. *Proc. Natl. Acad. Sci. U.S.A.*, 102,

7157–7162.

100. Eichman,B.F., Mooers,B.H.M., Alberti,M., Hearst,J.E. and Ho,P.S. (2001) The crystal structures of psoralen cross-linked DNAs:

drug-dependent formation of holliday junctions. *J. Mol. Biol.*, 308, 15–26.

101. Adams,A., Guss,J.M., Collyer,C.A., Denny,W.A. and Wakelin,L.P.G. (2000) A novel form of intercalation involving four DNA duplexes in an acridine-4-carboxamide complex of d(CGTACG)₂. *Nucleic Acids Res.*, 28, 4244–4253.

102. Thorpe,J.H., Hobbs,J.R., Todd,A.K., Denny,W.A., Charlton,P. and Cardin,C.J. (2000) Guanine specific binding at a DNA junction formed by d CG(5-BrU)ACG 2 with a topoisomerase poison in the presence of Co²⁺ ions. *Biochem.*, 39, 15055–15061.

103. Teixeira,S.C.M., Thorpe,J.H., Todd,A.K., Powell,H.R., Adams,A., Wakelin,L.P.G., Denny,W.A. and Cardin,C.J. (2002) Structural characterisation of bisintercalation in higher-order DNA at a junction-like quadruplex. *J. Mol. Biol.*, 323, 167–171.

104. Hopcroft,N.H., Brogden,A.L., Searcey,M. and Cardin,C.J. (2006) X-ray crystallographic study of DNA duplex cross-linking: simultaneous binding to two d (CGTACG) 2 molecules by a bis (9-aminoacridine-4-carboxamide) derivative. *Nucleic Acids Res.*, 34, 6663–6672.

Singh,H., Singh,H., Sharma,S., Mohinder,P. and Bedi,S. (2015) Chemotherapeutic potential of acridine analogs: an ample review. *Heterocycles*, 91, 2043–2085.

105. Read,M., Harrison,R.J., Romagnoli,B., Tanious,F.A., Gowan,S.H., Reszka,A.P., Wilson,W.D., Kelland,L.R. and Neidle,S. (2001)

Structure-based design of selective and potent g

quadruplex-mediated telomerase inhibitors. *Proc. Natl. Acad. Sci. U.S.A.*, 98, 4844–4849.

106. Chien,C.-M., Wu,P.-C., Satange,R., Chang,C.-C., Lai,Z.-L., Hagler,L.D., Zimmerman,S.C. and Hou,M.-H. (2020) Structural basis for targeting T:T mismatch with triaminotriazine-acridine conjugate induces a U-Shaped Head-to-Head four-way junction in CTG repeat DNA. *J. Am. Chem. Soc.*, 142, 11165–11172.

107. Herná'ndez,A.F., Parro'n,T., Tsatsakis,A.M., Requena,M.,

Alarco'n,R. and Lo'pez-Guarnido,O. (2013) Toxic effects of pesticide mixtures at a molecular level: their relevance to human health.

Toxicology, 307, 136–145.

108. Xia,J., Mei,Q. and Rosenberg,S.M. (2019) Tools to live by: bacterial DNA structures illuminate cancer. *Trends Genet.*, 35, 383–395.

109. Scully,R., Panday,A., Elango,R. and Willis,N.A. (2019) DNA double-strand break repair-pathway choice in somatic mammalian cells. *Nat. Rev. Mol. Cell Biol.*, 20, 698–714.

110. Vos,M. (2009) Why do bacteria engage in homologous recombination? *Trends Microbiol.*, 17, 226–232.

111. West,S.C. (2003) Molecular views of recombination proteins and their control. *Nat. Rev. Mol. Cell Biol.*, 4, 435–445.

112. Xia,J., Chen,L.-T., Mei,Q., Ma,C.-H., Halliday,J.A., Lin,H.-Y., Magnan,D., Pribis,J.P., Fitzgerald,D.M., Hamilton,H.M. et al. (2016) Holliday junction trap shows how cells use recombination and a junction-guardian role of RecQ helicase. *Sci. Adv.*, 2, e1601605.

113. Cassell,G.D. and Segall,A.M. (2003) Mechanism of inhibition of site-specific recombination by the holliday junction-trapping peptide WKHYYN: insights into phage h Integrase-mediated strand exchange. *J. Mol. Biol.*, 327, 413–429.

114. Ghosh,K., Lau,C.K., Guo,F., Segall,A.M. and Van Duyne,G.D. (2005) Peptide trapping of the holliday junction

intermediate in Cre-loxP Site-specific recombination *. J. Biol. Chem., 280, 8290–8299.

115. McGlynn,P. and Lloyd,R.G. (2001) Rescue of stalled replication forks by recg: simultaneous translocation on the leading and lagging strand templates supports an active DNA unwinding model of fork reversal and holliday junction formation. Proc. Natl. Acad. Sci. U.S.A., 98, 8227–8234.
116. Kepple,K.V., Boldt,J.L. and Segall,A.M. (2005) Holliday junction-binding peptides inhibit distinct junction-processing enzymes. Proc. Natl. Acad. Sci. U.S.A., 102, 6867–6872.
117. Gunderson,C.W. and Segall,A.M. (2006) DNA repair, a novel antibacterial target: holliday junction-trapping peptides induce DNA damage and chromosome segregation defects. Mol. Microbiol., 59, 1129–1148.
118. Boldt,J.L., Pinilla,C. and Segall,A.M. (2004) Reversible inhibitors of h Integrase-mediated recombination efficiently trap holliday junction intermediates and form the basis of a novel assay for junction resolution*. J. Biol. Chem., 279, 3472–3483.
119. Rideout,M.C., Naili,I., Boldt,J.L., Flores-Fujimoto,A., Patra,S., Rostron,J.E. and Segall,A.M. (2013) wrwyrggrywrw is a single-chain functional analog of the holliday junction-binding homodimer,(wrwycr) 2. Peptides, 40, 112–122.
120. Kepple,K.V., Patel,N., Salamon,P. and Segall,A.M. (2008) Interactions between branched DNAs and peptide inhibitors of DNA repair. Nucleic Acids Res., 36, 5319.
121. Bolla,M.L., Azevedo,E.V., Smith,J.M., Taylor,R.E., Ranjit,D.K., Segall,A.M. and McAlpine,S.R. (2003) Novel antibiotics: macrocyclic peptides designed to trap holliday junctions. Org. Lett., 5, 109–112.
122. Pan,P.-S., Curtis,F.A., Carroll,C.L., Medina,I., Liotta,L.A., Sharples,G.J. and McAlpine,S.R. (2006) Novel antibiotics: C-2 symmetrical macrocycles inhibiting holliday junction DNA binding by E. coli RuvC. Bioorg. Med. Chem., 14, 4731–4739.
123. Bonner,W.M., Redon,C.E., Dickey,J.S., Nakamura,A.J., Sedelnikova,O.A., Solier,S. and Pommier,Y. (2008) γ H2AX and cancer. Nat. Rev. Cancer, 8, 957.
124. Panier,S. and Boulton,S.J. (2014) Double-strand break repair: 53BP1 comes into focus. Nat. Rev. Mol. Cell Biol., 15, 7–18.
125. Apostolopoulos,V., Bojarska,J., Chai,T.-T., Elnagdy,S., Kaczmarek,K., Matsoukas,J., New,R., Parang,K., Lopez,O.P., Parhiz,H. et al. (2021) A global review on short peptides: frontiers and perspectives. Molecules, 26, 430.
126. Ranjit,D.K., Rideout,M.C., Nefzi,A., Ostresh,J.M., Pinilla,C. and Segall,A.M. (2010) Small molecule functional analogs of peptides that inhibit h site-specific recombination and bind holliday junctions. Bioorg. Med. Chem. Lett., 20, 4531–4534.
127. Rideout,M.C., Boldt,J.L., Vahi-Ferguson,G., Salamon,P., Nefzi,A., Ostresh,J.M., Giulianotti,M., Pinilla,C. and Segall,A.M. (2011) Potent antimicrobial small molecules screened as inhibitors of tyrosine recombinases and holliday junction-resolving enzymes. Mol. Diversity, 15, 989–1005.
128. Howell,L.A., Bowater,R.A., O'Connell,M.A., Reszka,A.P., Neidle,S. and Searcey,M. (2012) Synthesis of small molecules targeting multiple DNA structures using click chemistry. ChemMedChem, 7, 792–804.
129. Yin,Q., Liu,X., Hu,L., Song,Q., Liu,S., Huang,Q., Geng,Z., Zhu,Y., Li,X., Fu,F. et al. (2021) VE-822, a novel DNA holliday junction stabilizer, inhibits homologous recombination repair and triggers DNA damage response in osteogenic sarcomas. Biochem. Pharmacol., 193, 114767.
130. Kasthuber,E.R. and Lowe,S.W. (2017) Putting p53 in context. Cell, 170, 1062–1078.
131. MacLaine,N.J. and Hupp,T.R. (2011) How phosphorylation controls p53. Cell Cycle, 10, 916–921.
132. Liu,Q., Turner,K.M., Yung,Alfred, Chen,W.K. and Zhang,W. (2014) Role of AKT signaling in DNA repair and clinical response to cancer therapy. Neuro-Oncology, 16, 1313–1323.
133. Willmore,E., de Caux,S., Sunter,N.J., Tilby,M.J., Jackson,G.H., Austin,C.A. and Durkacz,B.W. (2004) A novel DNA-

dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. *Blood*, 103, 4659–4665.

134. Kato,T., Sato,N., Hayama,S., Yamabuki,T., Ito,T., Miyamoto,M., Kondo,S., Nakamura,Y. and Daigo,Y. (2007) Activation of holliday junction–recognizing protein involved in the chromosomal stability and immortality of cancer cells. *Cancer Res.*, 67, 8544–8553.

135. Fokas,E., Prevo,R., Pollard,J.R., Reaper,P.M., Charlton,P.A., Cornelissen,B., Vallis,K.A., Hammond,E.M., Olcina,M.M., Gillies McKenna,W. et al. (2012) Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. *Cell Death. Dis.*, 3, e441.

136. O'Connor,M.J. (2015) Targeting the DNA damage response in cancer. *Mol. Cell*, 60, 547–560.

137. Pilie',P.G., Tang,C., Mills,G.B. and Yap,T.A. (2019) State-of-the-art strategies for targeting the DNA damage response in cancer. *Nat. Rev. Clin. Oncol.*, 16, 81–104.

138. Duskova,K., Lejault,P., Benchimol,E', Guillot,R., Britton,S., Granzhan,A. and Monchaud,D. (2020) DNA junction ligands trigger DNA damage and are synthetic lethal with DNA repair inhibitors in cancer cells. *J. Am. Chem. Soc.*, 142, 424–435.

139. Zell,J., Duskova,K., Chouh,L., Bossaert,M., Che'ron,N., Granzhan,A., Britton,S. and Monchaud,D. (2021) Dual targeting of higher-order DNA structures by azacryptands induces DNA junction-mediated DNA damage in cancer cells. *Nucleic Acids Res.*, 49, 10275–10288.

140. Hall,C.E. and Cavalieri,L.F. (1961) Four-stranded DNA as determined by electron microscopy. *J. Cell Biol.*, 10, 347–351.

141. Jensch,F. and Kemper,B. (1986) Endonuclease VII resolves.

142. Stojanovic,M.N. and Landry,D.W. (2002) Aptamer-based colorimetric probe for cocaine. *J. Am. Chem. Soc.*, 124, 9678–9679.

143. Kato,T., Yano,K., Ikebukuro,K. and Karube,I. (2000) Interaction of three-way DNA junctions with steroids. *Nucleic Acids Res.*, 28, 1963–1968.

144. Stojanovic',M.N., Green,E.G., Semova,S., Nikic',D.B. and Landry,D.W. (2003) Cross-reactive arrays based on three-way junctions. *J. Am. Chem. Soc.*, 125, 6085–6089.

145. Oleksi,A., Blanco,A.G., Boer,R., Uso'n,I., Aymam'i,J., Rodger,A., Hannon,M.J. and Coll,M. (2006) Molecular recognition of a three-way DNA junction by a metallosupramolecular helicate. *Angew. Chem. Int. Ed.*, 45, 1227–1231.

146. Boer,D.R., Kerckhoffs,J.M., Parajo,Y., Pascu,M., Uso'n,I., Lincoln,P., Hannon,M.J. and Coll,M. (2010) Self-Assembly of functionalizable two-component 3D DNA arrays through the induced formation of DNA three-way-junction branch points by supramolecular cylinders. *Angew. Chem. Int. Ed.*, 49, 2336–2339.

147. Malina,J., Hannon,M.J. and Brabec,V. (2007) Recognition of DNA three-way junctions by metallosupramolecular cylinders: gel electrophoresis studies. *Chem. Eur. J.*, 13, 3871–3877.

148. Cerasino,L., Hannon,M.J. and Sletten,E. (2007) DNA three-way junction with a dinuclear iron (II) supramolecular helicate at the center: a NMR structural study. *Inorg. Chem.*, 46, 6245–6251.

149. Cardo,L., Sadovnikova,V., Phongtongpasuk,S., Hodges,N.J. and Hannon,M.J. (2011) Arginine conjugates of metallo-supramolecular cylinders prescribe helicity and enhance DNA junction binding and cellular activity. *Chem. Commun.*, 47, 6575–6577.

150. Gamba,I., Rama,G., Ortega-Carrasco,E., Mare'chal,J.-D., Mart'inez-Costas,J., Va'zquez,M.E. and Lo'pez,M.V. (2014) Programmed stereoselective assembly of DNA-binding helical metallopeptides. *Chem. Commun.*, 50, 11097–11100.

151. Go´mez-Gonza´lez,J., Pe´rez,Y., Sciortino,G., Roldan-Mart´ın,L., Mart´inez-Costas,J., Mare´chal,J.-D., Alfonso,I., Va´zquez Lo´pez,M. and Va´zquez,M.E. (2021) Dynamic stereoselection of peptide helicates and their selective labeling of DNA replication foci in cells. *Angew. Chem. Int. Ed.*, 60, 8859–8866.
152. Vuong,S., Stefan,L., Lejault,P., Rousselin,Y., Denat,F. and Monchaud,D. (2012) Identifying three-way DNA junction-specific small-molecules. *Biochimie*, 94, 442–450.
153. Novotna,J., Laguerre,A., Granzhan,A., Pirrotta,M., Teulade-Fichou,M.-P. and Monchaud,D. (2015) Cationic azacryptands as selective three-way DNA junction binding agents. *Org. Biomol. Chem.*, 13, 215–222.
154. Stefan,L., Bertrand,B., Richard,P., Le Gendre,P., Denat,F., Picquet,M. and Monchaud,D. (2012) Assessing the differential affinity of small molecules for noncanonical DNA structures. *ChemBioChem*, 13, 1905–1912.
155. Barros,S.A. and Chenoweth,D.M. (2014) Recognition of nucleic acid junctions using triptycene-based molecules. *Angew. Chem. Int. Ed.*, 53, 13746–13750.
156. Guyon,L., Pirrotta,M., Duskova,K., Granzhan,A., Teulade-Fichou,M.-P. and Monchaud,D. (2018) TWJ-Screen: an isothermal screening assay to assess ligand/DNA junction interactions in vitro. *Nucleic Acids Res.*, 46, e16.
157. Duskova,K., Lamarche,J., Amor,S., Caron,C., Queyriaux,N., Gaschard,M., Penouilh,M.-J., de Robillard,G., Delmas,D., Devillers,C.H. et al. (2019) Identification of three-way DNA junction ligands through screening of chemical libraries and validation by complementary in vitro assays. *J. Med. Chem.*, 62, 4456–4466.
158. Zhu,J., Haynes,C.J.E., Kieffer,M., Greenfield,J.L., Greenhalgh,R.D., Nitschke,J.R. and Keyser,U.F. (2019) FeII4L4 tetrahedron binds to nonpaired DNA bases. *J. Am. Chem. Soc.*, 141, 11358–11362.
159. Yang,Z., Chen,Y., Li,G., Tian,Z., Zhao,L., Wu,X., Ma,Q., Liu,M. and Yang,P. (2018) Supramolecular recognition of three way junctions DNA by a cationic calix [3]carbazole. *Chem. Eur. J.*, 24, 6087–6093.
160. Yu,H., Wang,X., Fu,M., Ren,J. and Qu,X. (2008) Chiral metallo-supramolecular complexes selectively recognize human telomeric G-quadruplex DNA. *Nucleic Acids Res.*, 36, 5695–5703.
161. Zhao,C., Geng,J., Feng,L., Ren,J. and Qu,X. (2011) Chiral metallo-supramolecular complexes selectively induce human telomeric G-Quadruplex formation under salt-deficient conditions. *Chem. Eur. J.*, 17, 8209–8215.
162. Ducani,C., Leczkowska,A., Hodges,N.J. and Hannon,M.J. (2010) Noncovalent DNA-Binding metallo-supramolecular cylinders prevent DNA transactions in vitro. *Angew. Chem. Int. Ed.*, 49, 8942–8945.
163. Go´mez-Gonza´lez,J., Mart´inez-Castro,L., Tolosa-Barrilero,J., Alcalde-Ordo´n˜ez,A., Learte-Aymam´ı,S., Mascaren˜as,J.L., Garc´ıa-Mart´inez,J.C., Mart´inez-Costas,J., Mare´chal,J.-D. and Lo´pez,M.V. (2022) Selective recognition of A/T-rich DNA 3-way junctions with a three-fold symmetric tripeptide. *Chem. Commun.*, 58, 7769–7772.
164. McLuckie,K.I.E., Di Antonio,M., Zecchini,H., Xian,J., Caldas,C., Krippendorff,B.F., Tannahill,D., Lowe,C. and Balasubramanian,S. (2013) G-Quadruplex DNA as a molecular target for induced synthetic lethality in cancer cells. *J. Am. Chem. Soc.*, 135, 9640–9643.

165. Wang,J.C. (2002) Cellular roles of DNA topoisomerases: a molecular perspective. *Nat. Rev. Mol. Cell Biol.*, 3, 430–440.
166. Szlachta,K., Manukyan,A., Raimer,H.M., Singh,S., Salamon,A., Guo,W., Lobachev,K.S. and Wang,Y.-H. (2020) Topoisomerase II contributes to DNA secondary structure-mediated double-stranded breaks. *Nucleic Acids Res.*, 48, 6654–6671.
167. Chardon,F., Japaridze,A., Witt,H., Velikovsky,L., Chakraborty,C., Wilhelm,T., Dumont,M., Yang,W., Kikuti,C. and Gangnard,S. (2022) CENP-B-mediated DNA loops regulate activity and stability of human centromeres. *Mol. Cell*, 82, 1751–1767.
168. Canˆeque,T., Muˆller,S. and Rodriguez,R. (2018) Visualizing biologically active small molecules in cells using click chemistry. *Nat. Rev. Chem.*, 2, 202–215.
169. Williamson,J.R., Raghuraman,M. and Cech,T.R. (1989) Monovalent cation-induced structure of telomeric DNA: the G-quartet model. *Cell*, 59, 871–880.
170. Sundquist,W.I. and Klug,A. (1989) Telomeric DNA dimerizes by formation of guanine tetrads between hairpin loops. *Nature*, 342, 825.
171. Sun,D.Y., Thompson,B., Cathers,B.E., Salazar,M., Kerwin,S.M., Trent,J.O., Jenkins,T.C., Neidle,S. and Hurley,L.H. (1997) Inhibition of human telomerase by a G-quadruplex-interactive compound. *J. Med. Chem.*, 40, 2113–2116.
172. Wang,Y.-H., Yang,Q.-F., Lin,X., Chen,D., Wang,Z.-Y., Chen,B., Han,H.-Y., Chen,H.-D., Cai,K.-C., Li,Q. et al. (2021) G4LDB 2.2: a database for discovering and studying G-quadruplex and i-Motif ligands. *Nucleic Acids Res.*, 50, D150–D160.
173. De Cian,A., DeLemos,E., Mergny,J.-L., Teulade-Fichou,M.-P. and Monchaud,D. (2007) Highly efficient G-quadruplex recognition by bisquinolinium compounds. *J. Am. Chem. Soc.*, 129, 1856–1857.
174. Raguseo,F., Chowdhury,S., Minard,A. and Di Antonio,M. (2020) Chemical-biology approaches to probe DNA and RNA G-quadruplex structures in the genome. *Chem. Commun.*, 56, 1317–1324.
175. Huppert,J.L. and Balasubramanian,S. (2005) Prevalence of quadruplexes in the human genome. *Nucleic Acids Res.*, 33, 2908–2916.
176. Bedrat,A., Lacroix,L. and Mergny,J.-L. (2016) Re-evaluation of G-quadruplex propensity with G4Hunter. *Nucleic Acids Res.*, 44, 1746–1759.
179. Goronzy, Isabel N., Quinodoz, Sofia A., Jachowicz, Joanna W., Ollikainen, Noah, Bhat, Prashant, Guttman, Mitchell. (2022) Simultaneous mapping of 3D structure and nascent RNAs argues against nuclear compartments that preclude transcription. *Scopus*, 1-20.
180. Chargaff,E., Zamenhof,S. and Green,C. (1950) Human desoxypentose nucleic acid: composition of human desoxypentose nucleic acid. *Nature*, 165, 756–757.
181. Watson,J.D. and Crick,F.H. (1953) Molecular structure of nucleic acids. *Nature*, 171, 737–738.
182. Malyshev,D.A., Dhami,K., Lavergne,T., Chen,T., Dai,N., Foster,J.M., Correˆa,I.R. and Romesberg,F.E. (2014) A semi-synthetic organism with an expanded genetic alphabet. *Nature*, 509, 385–388.